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Grace E. Kim, PHD,y Lawrence H. Young, MDyzSEE PAGE 47A MP-activated protein kinase (AMPK) is a molec-ular energy sensor that is essential to the stressresponse in the heart (1). AMPK is activated
during energy imbalance, when the ADP- or AMP-to-
ATP ratio increases. Because few proteins have adenine
nucleotide binding domains, the activation of a protein
kinase, which phosphorylates numerous downstream
proteins, ampliﬁes the energy stress response. AMP
and ADP binding to AMPK enhances the phosphoryla-
tion of the critical Thr172-activating site by promoting
the activity of the upstream kinase liver kinase B1
(LKB1), which is also present in the heart. When acti-
vated, AMPK signals the cell to generate ATP through
substrate metabolism and to conserve energy by limiting
anabolic pathways (1).
The LKB1-AMPK axis has emerged as a master
metabolic regulator with pleiotropic actions in the
heart. During ischemia, there is rapid and robust acti-
vation of endogenous left ventricular (LV) AMPK,
which limits energy depletion by stimulating glucose
uptake and glycolysis and increases autophagy and
inhibits protein synthesis (1). Mice with genetically
inactivated AMPK are predisposed to ischemia-
reperfusion injury with exaggerated necrosis and
apoptosis (2,3). Conversely, small-molecule AMPK ac-
tivators prevent myocardial injury during ischemia-
reperfusion (4). Furthermore, agents that activate
AMPK may also have beneﬁt in experimental heart
failure (5).*Editorials published in the Journal of the American College of Cardiology
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vide initial evidence that atrial AMPK is activated
during atrial ﬁbrillation (AF). Using a canine model,
they demonstrate increased phosphorylation of the
AMPK Thr172 site in left atrial tissue after 1 week of
rapid pacing-induced AF. They also found that pacing
isolated atrial myocytes at 2 Hz increased the
AMP/ATP ratio compared to that in quiescent cells.
Increases in the AMP/ATP ratio have also been seen in
experimental AF models (7), reﬂecting alterations in
metabolic pathways and the increased energy use
required to maintain ionic gradients during rapid
atrial rhythm. In addition to changes in energetics,
novel mechanisms might also contribute to AMPK
activation in AF, as is the case in the ischemic
heart, where secreted cytokines amplify AMPK acti-
vation (8,9).The physiological and cell signaling consequences
of AMPK activation in AF are all important but were
not examined in this study. However, the effects of
AMPK inhibition and activation during metabolic
stress were explored in canine atrial myocytes, as a
possible window into understanding the role of AMPK
in AF. Myocytes were incubated with pyruvate as the
sole exogenous fuel source and a very high concen-
tration of deoxyglucose, which is not metabolized
beyond deoxyglucose-6-phosphate. Such conditions
force cells to rely on nonglycolytic metabolism and
to deplete the inorganic phosphate needed for
cellular ATP synthesis. Metabolic inhibition reduced
atrial calcium transients and cell contractility, which
partially recovered unless AMPK was inhibited with
the pharmacological kinase inhibitor compound C.
Although kinase inhibitors lack speciﬁcity (10), these
results suggest that AMPK activation is an important
adaptive mechanism during metabolic imbalance in
atrial cells.
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60Reductions in calcium transients and contractility
during AMPK inhibition were associated with a
reduced NCX and L-type Ca2þ (Cav1.2) channel ac-
tivity. Cav1.2 and NCX1 were identiﬁed in macromo-
lecular complexes that also contained AMPK, raising
the question as to whether AMPK might phosphory-
late these channels. Kinases recognize stereotypic
amino acid sequences within proteins, and AMPK
prefers serine residues that are ﬂanked by hydro-
phobic amino acids (11). Because neither Cav1.2
nor NCX1 contains a classical AMPK phosphoryla-
tion sequence, it is more likely that indirect mecha-
nisms were responsible for the physiological effects
observed.
The decreased Cav1.2 channel activity likely
contributed to the reduction of contractility observed
during metabolic inhibition in isolated cardio-
myocytes treated with compound C. How these
changes might contribute to AF development is less
clear. Cav1.2 channel expression is normal in parox-
ysmal but decreased in persistent AF patients (12),
whereas NCX channel expression is increased in
paroxysmal but normal in persistent AF patients (13).
The authors postulate that intrinsic AMPK activation
during AF might prevent shortening of the atrial
action potential duration, which could promote re-
entry and the perpetuation of AF.
The hypothesis that AMPK inactivation contributes
to the development or perpetuation of AF is consis-
tent with prior ﬁndings that spontaneous AF occurs in
mice with inactive AMPK due to genetic deletion of
the upstream kinase LKB1. These mice also develop
substantial atrial ﬁbrosis, LV hypertrophy and LV
contractile dysfunction (14,15). LKB1 deletion also
severely affects early atrial electrophysiology, with
chamber-speciﬁc neonatal reduction in the atrial
expression of Nav1.5, Cx 40 and 43, as well as atrial
conduction slowing, before the onset of AF (16).
Because LKB1 also regulates 12 other AMPK-related
kinases, the extent to which AMPK is primarily
responsible for these electrophysiological ﬁndings
requires further investigation.Mutations in human AMPK are also known to cause
AF as part of the familial PRKAG2 syndrome. Some of
these mutations cause a gain-of-function change in
AMPK activity (17), which would appear to contradict
the antiﬁbrillatory effects of AMPK proposed by
Harada et al. (6). However, mutations in PRKAG2
have a continuously high level of AMPK activation,
promoting glucose uptake in excess of metabolic
demand and inhibiting glucose oxidation, which
shunts glucose into glycogen. The consequent
glycogen overload leads to persistence of atrial-
ventricular muscle bridges during cardiac devel-
opment, resulting in the Wolff-Parkinson-White
syndrome. It also leads to post-natal atrial and ven-
tricular remodeling, conduction system disease and
atrial arrhythmias. Interestingly, atrial glycogen
buildup is also associated with pacing-induced AF in
goats (18), raising the possibility that more long-term
AMPK activation induced by AF might contribute to
secondary glycogen deposition.
How do these results relate to human AF? The
authors also assessed AMPK phosphorylation in right
atrial appendage tissue excised from patients with
either paroxysmal or chronic AF undergoing cardiac
surgery. Although the fraction of phosphorylated
AMPK was increased in paroxysmal AF, it was de-
creased in chronic AF. Whether these initial ﬁndings
are associated with changes in AMPK activity or lead
to alterations in downstream pathways is important
to understand and requires further investigation.
AMPK is emerging as a physiological regulator with
important roles in type 2 diabetes and cancer. Potent
pharmacological AMPK activators are being devel-
oped for therapeutic purposes, and it will be of
interest to determine whether these agents might be
effective in the treatment or prevention of atrial
arrhythmias in patients with metabolic disease.
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